Connection
Cindy O'Bryant to Lung Neoplasms
This is a "connection" page, showing publications Cindy O'Bryant has written about Lung Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.286 |
|
|
|
-
O'Bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother. 2013 Feb; 47(2):189-97.
Score: 0.149
-
Chen NC, Zemplenyi AT, Adamson B, Kaizer AM, O'Bryant CL, McQueen RB, Anderson KE. Using Regression Discontinuity in Time to Strengthen Real-World Evidence: A Case Study in Lung Cancer. Med Decis Making. 2026 Jul; 46(5):601-623.
Score: 0.093
-
Wong KM, Noonan S, O'Bryant C, Jimeno A. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer. Drugs Today (Barc). 2015 Mar; 51(3):161-70.
Score: 0.043